AWMSG approves tiotropium
14th December 2018
The All Wales Medicines Strategy Group (AWMSG) has approved the use of tiotropium (Spiriva® Respimat®) as an option for use within NHS Wales as add-on maintenance bronchodilator treatment in patients aged ≥6years with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
Recent news
- RPS Wales Palliative and End of Life Care Policy
- NICE guidelines for COPD updated
- AWMSG approves tiotropium
- Palliative Care Formulary migration to MedicinesComplete - January 2019
- Supplementary information on cannabis-based products for medicinal use
- Report on action taken on ambulatory syringe drivers
- NICE consultation on cannabis-based products for medicinal use
- Guidance and information on prescribing and supply of cannabis-based products for medicinal use
- Instanyl (fentanyl) multidose nasal sprays discontinued
- Gabapentin and pregabalin to be controlled as class C drugs
News archive
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000